Economic Assessment in Resource-Constrained Systems: Individual-Level Simulation Model in Wet Age-Related Macular Degeneration and Diabetic Macular Oedema.

Autor: Li T; Putnam, 22-24 Torrington Place, Fitzrovia, London, WC1E 7HJ, UK., Berdunov V; Putnam, 22-24 Torrington Place, Fitzrovia, London, WC1E 7HJ, UK. vlad.berdunov@putassoc.com., Hamilton R; Moorfields Eye Hospital, London, UK., Rojas YG; Putnam, 22-24 Torrington Place, Fitzrovia, London, WC1E 7HJ, UK., Bührer C; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Cox O; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Postema R; Putnam, 22-24 Torrington Place, Fitzrovia, London, WC1E 7HJ, UK., Bagijn M; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Jazyk: angličtina
Zdroj: Ophthalmology and therapy [Ophthalmol Ther] 2024 Oct; Vol. 13 (10), pp. 2577-2597. Date of Electronic Publication: 2024 Aug 06.
DOI: 10.1007/s40123-024-00999-8
Abstrakt: Introduction: Cost-effectiveness analyses typically ignore healthcare system resource constraints. Ophthalmology is affected by resource constraints because of increasing disease prevalence and the use of resource-intensive treatments. This study evaluated the impact of resource constraints on the cost-effectiveness of faricimab 6 mg, compared with aflibercept 2 mg and ranibizumab biosimilar 0.5 mg, for treating wet age-related macular degeneration (wAMD) or diabetic macular oedema (DMO) over a 5-year horizon.
Methods: A microsimulation model estimated the impact of resource constraints on patients visits, delays, costs and quality-adjusted life-year (QALY) losses due to treatment delays at a typical UK National Health Service eye hospital treating 1500 patients with wAMD and 500 patients with DMO. Patient characteristics, treatment regimens and treatment intervals were informed using published literature and expert opinion. Resource constraint was represented by limiting the number of available intravitreal injection appointments per week, with growing demand caused by rising disease prevalence. The model compared outcomes across three scenarios; each scenario involved treating all patients with one of the three treatments.
Results: Over 5 years, in a resource-constrained hospital, compared with aflibercept, faricimab use resulted in the avoidance of 12,596 delays, saved GBP/£15,108,609 in cost and avoided the loss of 60.06 QALYs. Compared with ranibizumab biosimilar, faricimab use resulted in the avoidance of 18,910 delays, incurred £2,069,088 extra cost and avoided the loss of 105.70 QALYs, resulting in an incremental cost-effectiveness ratio of £19,574/QALY.
Conclusions: Accounting for resource constraints in health economic evaluation is crucial. Emerging therapies that are more durable and require less frequent clinic visits can reduce treatment delays, leading to improved QALY outcomes and reduced burden on healthcare systems. Faricimab reduced the number of delayed injections, leading to improved QALY outcomes for patients in a healthcare system with resource constraints. Faricimab is cost-saving when compared with aflibercept and cost-effective when compared with ranibizumab biosimilar.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje